Atorvastatin for eradication of Helicobacter pylori

The effect of adding atorvastatin to routine quadruple therapy for eradication of Helicobacter pylori

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161205031252N7

Enrollment

200

Registered

2018-06-11

Start date

2018-05-22

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: tablet Clarithromycin 500 mg twice daily, capsule Amoxicillin 1 g twice daily, tablet Bismuth 500 mg four times daily, capsule Esomeprazole 20 mg twice daily, and t

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years ]nfection with Helicobacter pylori Would like to participate in the study

Exclusion criteria

Exclusion criteria: Contraindications of Clarithromycin, Amoxicillin, Bismuth, Omeprazole or Atorvastatin

Design outcomes

Primary

Measure	Time frame
Eradication of Helicobacter pylori. Timepoint: 4 weeks after intervention. Method of measurement: Stool antigen test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Hormati

Ghoum University of Medical Sciences

Hormatia@muq.ac.ir+98 256122053

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026